TEL AVIV, Israel, April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May.
British Society for Rheumatology Annual Conference – April 24-26, 2023
Date: | April 24, 2023 |
Time: | 9:45am BST |
Venue: | Manchester Central Convention Complex, Manchester, UK and virtual |
Format: | Oral presentation: CCL24 Serum Concentration Predicts Both Vascular and Fibrotic Complications in Systemic Sclerosis: Rationale for a Biological Target Driven, Basket Trial Across Disease Subsets |
Presenter: | Professor Enrico De Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal Diseases, University of Leeds, UK |
Information: | https://www.rheumatology.org.uk/events-learning/conferences/annual-conference |
EASL Monothematic Conference on Biliary Fibrosis 2023 – May 12-13, 2023
Date: | May 12, 2023 |
Time: | 17:20-17:50 CEST |
Venue: | Grand Hotel Baglioni, Florence, Italy |
Format: | Poster presentation: Patient proteomic data and mouse model reinforce the proinflammatory role of CCL24 in cholestatic disease |
Session: | ePoster session 3 and break |
Presenter: | Matt Frankel, MD, Chief Medical Officer, Chemomab |
Information: |
In addition, Chemomab's corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.
Contacts:
Investors: | Investors & Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 (917) 734-7387 | Consulting Vice President, Investor & Public Relations |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Strategic Communications |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.10 |
| Daily Change: | -0.04 -1.27 |
| Daily Volume: | 89,156 |
| Market Cap: | US$16.090M |
August 21, 2025 August 14, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
